Japanese flu vaccine makers jack up price ahead of flu season; Supreme Court won't hear challenge to NY public schools vaccination requirement;

> Four Japanese flu vaccine makers have hiked their prices by 50% just ahead of the flu season. Story

> The Supreme Court will not hear a challenge to New York state's requirement that children get vaccinated before starting public school. Article

> Abivax is evaluating HeberNavasc, the new Cuban vaccine for the treatment of chronic hepatitis B in 8 countries. More

Suggested Articles

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.

Participation in clinical trials among Black people is low, FDA statistics show, even as drugmakers prioritize including them in COVID-19 shot trials.